These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 35075053)
21. In vitro characterization of the pyrazole-carrying synthetic cannabinoid receptor agonist 5F-3,5-AB-PFUPPYCA and its structural analogs. Deventer MH; Norman C; Reid R; McKenzie C; Nic Daéid N; Stove CP Forensic Sci Int; 2023 Feb; 343():111565. PubMed ID: 36640535 [TBL] [Abstract][Full Text] [Related]
22. "Spice"-related deaths in and around Munich, Germany: A retrospective look at the role of synthetic cannabinoid receptor agonists in our post-mortem cases over a seven-year period (2014-2020). Groth O; Roider G; Angerer V; Schäper J; Graw M; Musshoff F; Auwärter V Int J Legal Med; 2023 Jul; 137(4):1059-1069. PubMed ID: 37072496 [TBL] [Abstract][Full Text] [Related]
23. A subtle structural modification of a synthetic cannabinoid receptor agonist drastically increases its efficacy at the CB1 receptor. Yano H; Chitsazi R; Lucaj C; Tran P; Hoffman AF; Baumann MH; Lupica CR; Shi L bioRxiv; 2023 Jun; ():. PubMed ID: 37398099 [TBL] [Abstract][Full Text] [Related]
24. Synthetic cannabinoid receptor agonists: classification and nomenclature. Potts AJ; Cano C; Thomas SHL; Hill SL Clin Toxicol (Phila); 2020 Feb; 58(2):82-98. PubMed ID: 31524007 [No Abstract] [Full Text] [Related]
30. Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. Banister SD; Adams A; Kevin RC; Macdonald C; Glass M; Boyd R; Connor M; McGregor IS; Havel CM; Bright SJ; Vilamala MV; Lladanosa CG; Barratt MJ; Gerona RR Drug Test Anal; 2019 Feb; 11(2):279-291. PubMed ID: 30151911 [TBL] [Abstract][Full Text] [Related]
31. Shape matters: The application of activity-based in vitro bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug-infused papers seized in prisons. Antonides LH; Cannaert A; Norman C; NicDáeid N; Sutcliffe OB; Stove CP; McKenzie C Drug Test Anal; 2021 Mar; 13(3):628-643. PubMed ID: 33161649 [TBL] [Abstract][Full Text] [Related]
32. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014. Palamar JJ; Su MK; Hoffman RS Am J Drug Alcohol Abuse; 2016; 42(1):39-47. PubMed ID: 26678258 [TBL] [Abstract][Full Text] [Related]
33. Detection and quantitation of synthetic cannabinoid receptor agonists in infused papers from prisons in a constantly evolving illicit market. Norman C; Walker G; McKirdy B; McDonald C; Fletcher D; Antonides LH; Sutcliffe OB; Nic Daéid N; McKenzie C Drug Test Anal; 2020 Apr; 12(4):538-554. PubMed ID: 31944624 [TBL] [Abstract][Full Text] [Related]
34. NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity? Ametovski A; Cairns EA; Grafinger KE; Cannaert A; Deventer MH; Chen S; Wu X; Shepperson CE; Lai F; Ellison R; Gerona R; Blakey K; Kevin R; McGregor IS; Hibbs DE; Glass M; Stove C; Auwärter V; Banister SD ACS Chem Neurosci; 2021 Nov; 12(21):4020-4036. PubMed ID: 34676751 [TBL] [Abstract][Full Text] [Related]
35. Modulation of human T-type calcium channels by synthetic cannabinoid receptor agonists in vitro. Bladen C; Mirlohi S; Santiago M; Longworth M; Kassiou M; Banister S; Connor M Neuropharmacology; 2021 Apr; 187():108478. PubMed ID: 33600843 [TBL] [Abstract][Full Text] [Related]
36. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution. Banister SD; Connor M Handb Exp Pharmacol; 2018; 252():191-226. PubMed ID: 30105473 [TBL] [Abstract][Full Text] [Related]
37. Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs. Sparkes E; Boyd R; Chen S; Markham JW; Luo JL; Foyzun T; Zaman H; Fletcher C; Ellison R; McGregor IS; Santiago MJ; Lai F; Gerona RR; Connor M; Hibbs DE; Cairns EA; Glass M; Ametovski A; Banister SD Front Psychiatry; 2022; 13():1010501. PubMed ID: 36245876 [TBL] [Abstract][Full Text] [Related]
38. Synthetic cannabinoid receptor agonists are monoamine oxidase-A selective inhibitors. Hindson SA; Andrews RC; Danson MJ; van der Kamp MW; Manley AE; Sutcliffe OB; Haines TSF; Freeman TP; Scott J; Husbands SM; Blagbrough IS; Anderson JLR; Carbery DR; Pudney CR FEBS J; 2023 Jun; 290(12):3243-3257. PubMed ID: 36708234 [TBL] [Abstract][Full Text] [Related]
39. In vitro determination of the efficacy of illicit synthetic cannabinoids at CB Sachdev S; Vemuri K; Banister SD; Longworth M; Kassiou M; Santiago M; Makriyannis A; Connor M Br J Pharmacol; 2019 Dec; 176(24):4653-4665. PubMed ID: 31412133 [TBL] [Abstract][Full Text] [Related]
40. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB Pike E; Grafinger KE; Cannaert A; Ametovski A; Luo JL; Sparkes E; Cairns EA; Ellison R; Gerona R; Stove CP; Auwärter V; Banister SD Drug Test Anal; 2021 Jul; 13(7):1383-1401. PubMed ID: 33787091 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]